Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 May 20;38(15):1645-1647.
doi: 10.1200/JCO.20.00136. Epub 2020 Feb 25.

Is It Safe to Stop Anti-PD-1 Immunotherapy in Patients With Metastatic Melanoma Who Achieve a Complete Response?

Michael A Davies  1
Affiliations
Editorial

Is It Safe to Stop Anti-PD-1 Immunotherapy in Patients With Metastatic Melanoma Who Achieve a Complete Response?

Michael A Davies. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Atkins MB, Kunkel L, Sznol M, et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update. Cancer J Sci Am. 2000;6(suppl 1):S11–S14. - PubMed
    1. Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889–1894. - PMC - PubMed
    1. Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): Post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20:1239–1251. - PubMed
    1. Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30:582–588. - PMC - PubMed
    1. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535–1546. - PubMed

Publication types